Takeda Canada Inc. ("Takeda") is pleased to announce positive topline results for the Phase 3, randomized, multicenter, ...

Having your electricity disconnected is more common in Oklahoma than any other state.

During a Monday press conference, Chief Mike Bell said his department "found no substantiated criminal conduct related to the ...

The top of the Atlas School building crumbled Wednesday afternoon, spilling bricks onto the sidewalk in front of the more than century-old building. Yellow caution tape flapped in the wind as ...

Takeda’s oral tyrosine kinase 2 (TYK2) inhibitor has outperformed Bristol Myers Squibb’s (BMS) Sotyktu (deucravacitinib) in adults with moderate-to-severe plaque psoriasis (PsO). In the Phase III ...

武田下一代TYK2抑制剂达到3期临床主要终点武田（Takeda）今日宣布了一项随机、双盲、多中心3期临床试验的积极顶线结果。该研究在中重度斑块状银屑病（PsO）成人患者中，比较了其在研下一代、高选择性口服酪氨酸激酶2（TYK2）抑制剂zasocitinib（TAK-279）与获批TYK2抑制剂的疗效。顶线结果显示，在LATITUDE ...

Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated ...

Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated ...